Navier AI | $6,500,000 | (Dec 17, 2025)
AIR Platforms | $6,100,000 | (Dec 17, 2025)
Auxira Health | $7,800,000 | (Dec 17, 2025)
Certified by Founder
Lodge
Exeliom Biosciences
start up
France
- Dijon, Bourgogne-Franche-Comté
- 21/07/2023
- Series A
- $8,898,320
At Exeliom Biosciences, we develop single bacterial strain drug candidates to deliver first-in-class microbiome-based therapeutics (also known as Live Biotherapeutics) for the treatment of immune-mediated diseases, with specific focus on inflammatory bowel diseases (IBD), and Crohn’s Disease as a first indication
- Industry Pharmaceutical Manufacturing
- Website https://www.exeliombio.com/
- LinkedIn https://www.linkedin.com/company/nextbiotix/
Related People
Benjamin HadidaFounder
France -
Paris, Île-de-France
Biotech company builder and new therapeutic class explorer
Mirelo AI | $41,000,000 | (Dec 17, 2025)
Lucis (YC X25) | $8,500,000 | (Dec 17, 2025)
Verisoul | $8,800,000 | (Dec 17, 2025)
Aeovian Pharmaceuticals | $55,000,000 | (Dec 17, 2025)
Nanit | $50,000,000 | (Dec 17, 2025)
Culture Biosciences | Undisclosed Amount | (Dec 17, 2025)
YSE Beauty | $15,000,000 | (Dec 17, 2025)
Vital Lyfe | $24,000,000 | (Dec 17, 2025)
Dux Security | $9,000,000 | (Dec 17, 2025)